ABSTRACT

OBJECTIVE: The objective of this study was to explore differences/similarities in epidemiology and treatment of soft tissue sarcoma (STS) in EU5 (France, Germany, Italy, Spain, United Kingdom).

METHODOLOGY: CancerMPact® is a comprehensive oncology decision support resource. It can be utilized for market analysis, strategic planning, and identification of commercial opportunities in the U.S. Western Europe, Japan, and China. This resource is comprised of web-based integrated modules including Patient Metrics, Treatment Architecture, and Future Trends and Insights.

RESULTS: Among metastatic patients, 41% of mSTS in EU5, France was the most commonly used treatment in first-line therapy (35%), trabectedin and pazopanib were the second-line treatment (30%), and third-line treatment was in France and Spain second-line treatment was in France and Italy. Among metastatic patients, 50% for Line 1, 40% for Line 2, 30% for Line 3, and 20% for Line 4 was in metastatic treatment from a physician survey.

CONCLUSIONS: Incidence of STS in France, Germany, Italy, Spain, and UK were similar to France, Germany, Italy, Spain, and USA. Among metastatic patients, 41% of mSTS in EU5 France was the most commonly used treatment in first-line therapy (35%), trabectedin and pazopanib were the second-line treatment (30%), and third-line treatment was in France and Spain second-line treatment was in France and Italy. Among metastatic patients, 50% for Line 1, 40% for Line 2, 30% for Line 3, and 20% for Line 4 was in metastatic treatment from a physician survey.

The objective of this study was to explore differences/similarities in epidemiology and treatment of soft tissue sarcoma (STS) in EU5 (France, Germany, Italy, Spain, United Kingdom).

Epidemiology and Treatment of Soft Tissue Sarcoma (STS) in the EU5

Incidence and Prevalence of STS in EU5

Objective:

- The objective of this study was to explore differences/similarities in epidemiology and treatment of soft tissue sarcoma (STS) in EU5 (France, Germany, Italy, Spain, United Kingdom).

Methodology:

- CancerMPact® is a comprehensive oncology decision support resource. It can be utilized for market analysis, strategic planning, and identification of commercial opportunities in the U.S. Western Europe, Japan, and China. This resource is comprised of web-based integrated modules including Patient Metrics, Treatment Architecture, and Future Trends and Insights.

Results:

- Among metastatic patients, 41% of mSTS in EU5, France was the most commonly used treatment in first-line therapy (35%), trabectedin and pazopanib were the second-line treatment (30%), and third-line treatment was in France and Spain second-line treatment was in France and Italy. Among metastatic patients, 50% for Line 1, 40% for Line 2, 30% for Line 3, and 20% for Line 4 was in metastatic treatment from a physician survey.

Conclusions:

- Incidence of STS in France, Germany, Italy, Spain, and UK were similar to France, Germany, Italy, Spain, and USA. Among metastatic patients, 41% of mSTS in EU5 France was the most commonly used treatment in first-line therapy (35%), trabectedin and pazopanib were the second-line treatment (30%), and third-line treatment was in France and Spain second-line treatment was in France and Italy. Among metastatic patients, 50% for Line 1, 40% for Line 2, 30% for Line 3, and 20% for Line 4 was in metastatic treatment from a physician survey.

The objective of this study was to explore differences/similarities in epidemiology and treatment of soft tissue sarcoma (STS) in EU5 (France, Germany, Italy, Spain, United Kingdom).